Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Aeterna Zentaris reports AGHD diagnostic test positive results

Aeterna Zentaris has reported favorable top-line results of AEZS-130, a novel orally active small molecule that stimulates the secretion of growth hormone.

The company has completed a Phase 3 trial for use as a simple oral diagnostic test for adult growth hormone deficiency (AGHD).

The primary efficacy parameters show that the study achieved both specificity and sensitivity at a level of 90% or greater.

In addition, 8 of the 10 newly enrolled AGHD patients were correctly classified by a pre-specified peak GH threshold level.

The use of AEZS-130 was shown to be safe and well tolerated overall throughout the completion of this trial.

AEZS-130 works by stimulating a patient’s growth hormone secretion, which normally only occurs during sleep, after which a healthcare provider will measure how well the body responds to that stimulation based on the patient’s growth hormone levels over a period of time.

AEZS-130 has been granted orphan-drug designation by the US Food and Drug Administration (FDA) for use as a diagnostic test for growth hormone deficiency.

Aeterna Zentaris owns the worldwide rights to AEZS-130 which, if approved, would become the first orally administered diagnostic test for AGHD.

The company is currently proceeding with further detailed analyses of the data and preparing for a pre-new drug application (NDA) meeting with the FDA in the upcoming months, which would be followed by the filing of a NDA for the registration of AEZS-130 in the US.